Firefly Neuroscience, Inc. develops AI-enabled precision neuroscience tools built around EEG/ERP brain data, including its FDA 510(k)-cleared brain analytics technology, the BNA platform, the Evoke System and the CLEAR Platform. News about AIFF centers on commercialization of cognitive electrophysiology analytics, growth in brain scan volumes, expansion of its standardized EEG/ERP data repository, and the use of NVIDIA GPU acceleration for signal processing and biomarker discovery.
Recurring company updates also cover research applications in neurological and mental health conditions such as ADHD, depression, dementia, anxiety disorders, concussions and cognitive disorders; partnerships with clinics, researchers and institutional customers; integration of Evoke Neuroscience; and periodic financial results tied to equipment sales, rentals, per-use fees and services for projects or clinical studies.
Firefly Neuroscience (NASDAQ: AIFF) has completed its merger with WaveDancer and is now listed on Nasdaq. The company focuses on using AI to improve brain health outcomes through two key strategies:
1. Commercializing FDA-cleared Brain Network Analytics (BNA™) technology for neurologists in the US.
2. Partnering with CNS drug companies to advance new treatments for brain disorders.
BNA™ has shown promising results in patient care, reducing medication changes and improving recovery times. Firefly plans to make BNA™ commercially available to neurologists in 2025. The company has already partnered with Novartis, Takeda, and STALICLA SA, featuring in three publications in 2024. Firefly's proprietary database of over 17,000 patients across 12 disorders gives it a competitive advantage in developing clinical biomarkers.